3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
7
Stomach Neoplasms
4
Rectal Neoplasms
4
Neoplasm Metastasis
2
Colonic Neoplasms
2
Turcot syndrome
1
Recurrence
1
Neoplasms
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Colorectal Cancer
1
Gastrointestinal Neoplasms
1
Gastric Cancer Stage
1
Adenocarcinoma of the Lower Rectum
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
XELOX
×
1 year
×
Clear all
NCT07266025
2026-01-27
CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
30 enrolled